{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005168","form_type":"8-K/A","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2026-08-04T11:01:21+00:00","discovered_at":"2026-08-04T11:05:00.386483+00:00","generated_at":"2026-08-04T11:06:04.886743+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioCryst estimates $6.2-7.5M in severance costs for discovery program discontinuation","bullets":["Plan to discontinue internal discovery programs and close Birmingham, AL facility announced June 29, 2026.","One-time expenses of $6.2-7.5M for employee termination benefits and severance; $5.3-6.6M cash expenditures.","Facility closure costs (contract/lease termination, asset impairment) not yet estimable; further filing expected.","Restructuring part of strategic evolution to strengthen rare disease pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005168","json":"https://secwatch.observer/filing/0001171843-26-005168.json","markdown":"https://secwatch.observer/filing/0001171843-26-005168.md","text":"https://secwatch.observer/filing/0001171843-26-005168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184326005168/0001171843-26-005168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184326005168/f8ka_080326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:06:04.886743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}